Howells LM, et al. - Among patients (n=28, aged >18 y) with a histological diagnosis of metastatic colorectal cancer, researchers compared folinic acid/5-fluorouracil/oxaliplatin chemotherapy (FOLFOX) to FOLFOX + 2 g oral curcumin/d (CUFOX) with respect to safety, efficacy, quality of life, neurotoxicity, curcuminoids, and C-X-C-motif chemokine ligand 1 (CXCL1) in this phase IIa open-labelled randomized controlled trial. Participants were administered either FOLFOX or CUFOX. For both arms, the observed adverse event profiles were similar. The HR in the intention-to-treat population was 0.57 for progression-free survival (median of 171 and 291 d for FOLFOX and CUFOX, respectively) and was 0.34 for overall survival (median of 200 and 502 d for FOLFOX and CUFOX, respectively). With regard to the quality of life or neurotoxicity, both the arms did not differ significantly. In 15 of 18 patients taking CUFOX, curcumin glucuronide was detectable at levels >1.00 pmol/mL. CXCL1 was not significantly influenced over time by curcumin. Overall, findings revealed safety as well as tolerability of curcumin when used as an adjunct to FOLFOX chemotherapy in patients with metastatic colorectal cancer.